Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
for Additional Challenging-to-treat
.
Show all posts
Showing posts with label
for Additional Challenging-to-treat
.
Show all posts
Friday, April 15, 2016
FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
›
In continuation of my update on Daclatasvir Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvir,...
›
Home
View web version
